Industry news

Can the cancer moonshot help cure Big Pharma's big bad reputation?

Beth Snyder Bulik / FiercePharmaMarketing

Vice President Joe Biden's cancer moonshot initiative has been celebrated for its exuberance and chided for its too-small budget. But InTouch Solutions CEO Faruk Capan thinks there's a less obvious reason pharma should get on board with the idea: It might help salvage the industry's floundering reputation.

Advice for biopharmas in China? Mind the gap

Shannon Ellis / BioWorld

In China, meeting the country's unmet medical needs is a frequent topic of discussion. For biopharmas, that can mean filling the substantial gap between which drugs are available in developed markets and which are available for patients here.

11 April 2016

Tobira Therapeutics and Dong-A ST Enter Into License Agreements for Evogliptin and Cenicriviroc

Tobira Therapeutics, Inc. (NASDAQ:TBRA) and Dong-A ST Co., Ltd. (170900: Korea SE), today announced that the companies have entered into two separate licensing agreements. Tobira has acquired exclusive rights to develop and market evogliptin in combination with cenicriviroc (CVC) and as a single agent in the United States, Canada, Europe and Australia for all therapeutic indications. 

The biotech cycle: Some views from the top

Cormac Sheridan / BioWorld

After its fall meeting in Germany, EBD Group's BIO-Europe spring partnering meeting normally heads south to the warmer climes of Spain or Italy. This year, however, it headed north to Stockholm, where spring is still more a suggestion than a reality. The relative chill that greeted delegates arriving in Sweden's capital could be a metaphor for what's ahead for the biotechnology sector in the coming year.

Building a wall to keep companies in

Mari Serebrov / BioWorld Perscpectives

They may not realize it, but many Americans woke up this morning with their retirement portfolio worth less than it was a week ago. And it could be worth less tomorrow and even a year or a decade from now than it would have been – all because of Monday’s unilateral decision by the Department of Treasury to build an even higher wall, at the expense of investors, to keep U.S. businesses from moving out of the country.

Experts worry insulin getting too expensive for many in U.S. and worldwide

Eric Palmer / FeircePharma

Drugmakers have made great strides coming up with new treatments for diabetes as the disease gallops across the globe. But healthcare professionals are concerned that hormone insulin meds, often the key treatment, are getting too costly for many patients, even in the U.S. In developing countries, they say engineered insulin is automatically out of reach of many people while supplies of older, but cheaper, human insulin are becoming scarce.

Ascension Ventures' Matt Hermann on VC and healthtech

PitchBook Blog

We recently sat down with Ascension Ventures senior managing director Matt Hermann to talk about his firm's unique approach to investing and how VC investment in the healthcare sector has changed in recent years. Wonder what's next for the industry? 

Up up and away: 2015 pharma ad spending ties decade-old record

Beth Snyder Bulik / FiercePharmaMarketing

It's a tie. Pharma advertisers spent $5.4 billion in 2015, tying the previous industry record set in 2006, according to new data from Kantar Media. That's an increase of 19% over the category's $4.53 billion tally for 2014.

Nanoparticle 'cluster-bomb' penetrates tumors to reduce chemo doses

Michael Gibney / FierceDrudDelivery

A team of scientists from the U.S. and China have devised a type of nanoparticle containing yet more nanoparticles, together which form a "cluster-bomb" to improve tumor penetration.

New study highlights a gut pathway for red wine compound resveratrol

John Carroll / FierceBiotech

For years now resveratrol, a compound found in red wine, has intrigued and confounded researchers. It has repeatedly been linked to antiaging benefits, demonstrating antiatherosclerosis effects in animal studies and inspiring a $720 million buyout at GlaxoSmithKline.